{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:46:54Z","timestamp":1791776814192,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intraductal papillary mucinous neoplasms (IPMNs) are critical precursors to pancreatic ductal adenocarcinoma, a highly lethal cancer characterized by late detection and rapid progression. Here we integrate multi-region whole-genome and transcriptome sequencing to trace the evolution of IPMN, constructing detailed phylogenetic trees to provide insights into subclonal architectures and progression pathways. Our analysis identifies two distinct evolutionary trajectories: one driven by a single ancestral clone, and another involving multiple independent ancestral clones. We further explore the roles of mutational signatures and structural variants in promoting clonal evolution and the emergence of new subclones. Complementing these genomic findings, our transcriptomic analysis reveals unique gene expression profiles and variations in the immune landscape that correlate with different progression stages of IPMN. These insights reveal the complex molecular dynamics of IPMN heterogeneity and progression, highlighting the need to refine early detection and treatment strategies.<\/jats:p>","DOI":"10.1038\/s41467-026-69762-w","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:14:49Z","timestamp":1772590489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-6756","authenticated-orcid":false,"given":"Antonio","family":"Pea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4017-2037","authenticated-orcid":false,"given":"Xiaotong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Upstill-Goddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-4908","authenticated-orcid":false,"given":"Claudio","family":"Luchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor Patricia","family":"Schubert Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"Duthie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9552-4725","authenticated-orcid":false,"given":"Nigel B.","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euan J.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9542-9165","authenticated-orcid":false,"given":"Alessandra","family":"Pulvirenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Rebus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Piccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Sperandio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3160-0634","authenticated-orcid":false,"given":"Rita T.","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-8164","authenticated-orcid":false,"given":"Fieke E. M.","family":"Froeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-739X","authenticated-orcid":false,"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0362-5597","authenticated-orcid":false,"given":"Andrew V.","family":"Biankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-3196","authenticated-orcid":false,"given":"David C.","family":"Wedge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-3078","authenticated-orcid":false,"given":"David K.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"69762_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"69762_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pan.2023.12.009","volume":"24","author":"T Ohtsuka","year":"2024","unstructured":"Ohtsuka, T. et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 24, 255\u2013270 (2024).","journal-title":"Pancreatology"},{"key":"69762_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature19823","volume":"538","author":"F Notta","year":"2016","unstructured":"Notta, F. et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538, 378\u2013382 (2016).","journal-title":"Nature"},{"key":"69762_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495\u2013501 (2015).","journal-title":"Nature"},{"key":"69762_CR5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/2159-8290.CD-19-1508","volume":"10","author":"H Sakamoto","year":"2020","unstructured":"Sakamoto, H. et al. The evolutionary origins of recurrent pancreatic cancer. Cancer Discov. 10, 792\u2013805 (2020).","journal-title":"Cancer Discov."},{"key":"69762_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231\u2013240 (2020).","journal-title":"Nat. Genet."},{"key":"69762_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/SLA.0000000000001817","volume":"266","author":"A Pea","year":"2017","unstructured":"Pea, A. et al. Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann. Surg. 266, 133\u2013141 (2017).","journal-title":"Ann. Surg."},{"key":"69762_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17917-8","volume":"11","author":"M Noe","year":"2020","unstructured":"Noe, M. et al. Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nat. Commun. 11, 4085 (2020).","journal-title":"Nat. Commun."},{"key":"69762_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1053\/j.gastro.2019.06.001","volume":"157","author":"CG Fischer","year":"2019","unstructured":"Fischer, C. G. et al. Intraductal papillary mucinous neoplasms arise from multiple independent clones, each with distinct mutations. Gastroenterology 157, 1123\u20131137 e22 (2019).","journal-title":"Gastroenterology"},{"key":"69762_CR10","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1097\/PAS.0000000000000533","volume":"39","author":"O Basturk","year":"2015","unstructured":"Basturk, O. et al. A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am. J. Surg. Pathol. 39, 1730\u20131741 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"69762_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/ng.3764","volume":"49","author":"AP Makohon-Moore","year":"2017","unstructured":"Makohon-Moore, A. P. et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat. Genet. 49, 358\u2013366 (2017).","journal-title":"Nat. Genet."},{"key":"69762_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","volume":"70","author":"C Luchini","year":"2021","unstructured":"Luchini, C. et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut 70, 148\u2013156 (2021).","journal-title":"Gut"},{"key":"69762_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","volume":"578","author":"M Gerstung","year":"2020","unstructured":"Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122\u2013128 (2020).","journal-title":"Nature"},{"key":"69762_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network Electronic address, a.a.d.h.e. & Cancer Genome Atlas Research, N. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185\u2013203 e13 (2017).","journal-title":"Cancer Cell"},{"key":"69762_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"69762_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"69762_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","volume":"16","author":"EA Collisson","year":"2019","unstructured":"Collisson, E. A., Bailey, P., Chang, D. K. & Biankin, A. V. Molecular subtypes of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 16, 207\u2013220 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"69762_CR18","doi-asserted-by":"publisher","first-page":"107625","DOI":"10.1016\/j.celrep.2020.107625","volume":"31","author":"H Brunton","year":"2020","unstructured":"Brunton, H. et al. HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Rep. 31, 107625 (2020).","journal-title":"Cell Rep."},{"key":"69762_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-0716-0327-7_16","volume":"2120","author":"G Sturm","year":"2020","unstructured":"Sturm, G., Finotello, F. & List, M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. Methods Mol. Biol. 2120, 223\u2013232 (2020).","journal-title":"Methods Mol. Biol."},{"key":"69762_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"69762_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7744","volume":"6","author":"AK Witkiewicz","year":"2015","unstructured":"Witkiewicz, A. K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).","journal-title":"Nat. Commun."},{"key":"69762_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2018.10.029","volume":"156","author":"Y Omori","year":"2019","unstructured":"Omori, Y. et al. Pathways of progression from intraductal papillary mucinous neoplasm to pancreatic ductal adenocarcinoma based on molecular features. Gastroenterology 156, 647\u2013661 e2 (2019).","journal-title":"Gastroenterology"},{"key":"69762_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","volume":"22","author":"AA Connor","year":"2022","unstructured":"Connor, A. A. & Gallinger, S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat. Rev. Cancer 22, 131\u2013142 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"69762_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1136\/gutjnl-2020-321217","volume":"70","author":"K Fujikura","year":"2021","unstructured":"Fujikura, K. et al. Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions. Gut 70, 928\u2013939 (2021).","journal-title":"Gut"},{"key":"69762_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood, L. D., Canto, M. I., Jaffee, E. M. & Simeone, D. M. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology 163, 386\u2013402 e1 (2022).","journal-title":"Gastroenterology"},{"key":"69762_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-024-07359-3","volume":"629","author":"AM Braxton","year":"2024","unstructured":"Braxton, A. M. et al. 3D genomic mapping reveals multifocality of human pancreatic precancers. Nature 629, 679\u2013687 (2024).","journal-title":"Nature"},{"key":"69762_CR27","doi-asserted-by":"crossref","unstructured":"Habib, J. R. et al. Informing decision-making for transected margin reresection in intraductal papillary mucinous neoplasm-derived PDAC: an international multicenter study. Ann. Surg., ahead of print, (2024).","DOI":"10.1097\/SLA.0000000000006532"},{"key":"69762_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/path.6402","volume":"266","author":"KT Jamouss","year":"2025","unstructured":"Jamouss, K. T. et al. Tumor immune microenvironment alterations associated with progression in human intraductal papillary mucinous neoplasms. J. Pathol. 266, 40\u201350 (2025).","journal-title":"J. Pathol."},{"key":"69762_CR29","doi-asserted-by":"crossref","unstructured":"Pea, A. & Luchini, C. The importance of tumor microenvironment modulations in the progression of pancreatic intraductal papillary mucinous neoplasms(dagger). J. Pathol. 269, 126-129 (2025).","DOI":"10.1002\/path.6460"},{"key":"69762_CR30","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"69762_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34041-x","volume":"13","author":"LA Baldwin","year":"2022","unstructured":"Baldwin, L. A. et al. DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response. Nat. Commun. 13, 6539 (2022).","journal-title":"Nat. Commun."},{"key":"69762_CR32","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1158\/1078-0432.CCR-21-1355","volume":"28","author":"Y Wolf","year":"2022","unstructured":"Wolf, Y. & Samuels, Y. Intratumor heterogeneity and antitumor immunity shape one another bidirectionally. Clin. Cancer Res. 28, 2994\u20133001 (2022).","journal-title":"Clin. Cancer Res."},{"key":"69762_CR33","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/jamaoncol.2016.3916","volume":"3","author":"AA Connor","year":"2017","unstructured":"Connor, A. A. et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. JAMA Oncol. 3, 774\u2013783 (2017).","journal-title":"JAMA Oncol."},{"key":"69762_CR34","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1136\/gutjnl-2020-320730","volume":"70","author":"RC Grant","year":"2021","unstructured":"Grant, R. C. et al. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Gut 70, 1894\u20131903 (2021).","journal-title":"Gut"},{"key":"69762_CR35","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2019.02.012","volume":"176","author":"M Petljak","year":"2019","unstructured":"Petljak, M. et al. Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis. Cell 176, 1282\u20131294 e20 (2019).","journal-title":"Cell"},{"key":"69762_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"69762_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41586-020-1961-1","volume":"578","author":"K Yoshida","year":"2020","unstructured":"Yoshida, K. et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature 578, 266\u2013272 (2020).","journal-title":"Nature"},{"key":"69762_CR38","doi-asserted-by":"crossref","unstructured":"Brown, L. C. et al. LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. J. Immunother. Cancer 9, e001792 (2021).","DOI":"10.1136\/jitc-2020-001792"},{"key":"69762_CR39","doi-asserted-by":"publisher","first-page":"510","DOI":"10.21037\/tlcr-23-39","volume":"12","author":"Z He","year":"2023","unstructured":"He, Z. et al. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. Transl. Lung Cancer Res. 12, 510\u2013529 (2023).","journal-title":"Transl. Lung Cancer Res."},{"key":"69762_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30294-8","volume":"13","author":"B Holm","year":"2023","unstructured":"Holm, B., Barsuhn, S., Behrens, H. M., Kruger, S. & Rocken, C. The tumor biological significance of RNF43 and LRP1B in gastric cancer is complex and context-dependent. Sci. Rep. 13, 3191 (2023).","journal-title":"Sci. Rep."},{"key":"69762_CR41","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.pan.2017.07.007","volume":"17","author":"M Tanaka","year":"2017","unstructured":"Tanaka, M. et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17, 738\u2013753 (2017).","journal-title":"Pancreatology"},{"key":"69762_CR42","doi-asserted-by":"publisher","first-page":"e980","DOI":"10.1097\/SLA.0000000000003703","volume":"274","author":"A Pulvirenti","year":"2021","unstructured":"Pulvirenti, A. et al. Intraductal papillary mucinous neoplasms: have IAP consensus guidelines changed our approach?: results from a multi-institutional study. Ann. Surg. 274, e980\u2013e987 (2021).","journal-title":"Ann. Surg."},{"key":"69762_CR43","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994\u20131007 (2012).","journal-title":"Cell"},{"key":"69762_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"key":"69762_CR45","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","volume":"606","author":"CD Steele","year":"2022","unstructured":"Steele, C. D. et al. Signatures of copy number alterations in human cancer. Nature 606, 984\u2013991 (2022).","journal-title":"Nature"},{"key":"69762_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27079-w","volume":"12","author":"N Ansari-Pour","year":"2021","unstructured":"Ansari-Pour, N. et al. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat. Commun. 12, 6946 (2021).","journal-title":"Nat. Commun."},{"key":"69762_CR47","doi-asserted-by":"crossref","unstructured":"Dentro, S. C., Wedge, D. C. & Van Loo, P. Principles of reconstructing the subclonal architecture of cancers. Cold Spring Harb Perspect. Med. 7, a026625 (2017).","DOI":"10.1101\/cshperspect.a026625"},{"key":"69762_CR48","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med 17, 500\u2013503 (2011).","journal-title":"Nat. Med"},{"key":"69762_CR49","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178 (2015).","journal-title":"Nat. Genet."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69762-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:01:43Z","timestamp":1776060103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69762-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69762"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69762-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.K.C. has received consulting and lecture fees from Immodulon Therapeutics and Mylan, research funding from Astrazeneca, BMS GmbH & Co. KG, Merck, and Immodulon Therapeutics. MM reports honoraria from AstraZeneca, MSD Oncology, Ipsen, Hippocrates, Viatris, and Servier, and reports consulting or advisory role for AstraZeneca, MSD Oncology, and Janssen Oncology; research funding from Roche and other relationships (participation to protocol Steering Committees and Independent Data Monitoring Committee) with Novartis and OncoSil. FEMF has received research funding from Astrazeneca and Sierra Oncology, speakers fees from Servier Oncology, Viatris travel support from Viatris, and is in the advisory board of Astellas and Abbott. NBJ has received honorariums and delivered talks for Nanostring, 10x genomics, APkoya, and is the scientific advisory board for Galvani. C.L. has received funds from NTP (scientific advisor), MSD (speaker bureau), and Medica srl (speaker bureau). No potential conflicts of interest were disclosed by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3427"}}